Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) is a clinical‐stage biopharmaceutical company focused on the discovery and development of first‐in‐class and best‐in‐class immuno‐oncology therapies. The company’s research is centered on novel small‐molecule compounds and antibody‐based agents designed to enhance the body’s natural immune response against solid tumors and hematologic malignancies. Whitehawk’s pipeline includes a cyclin‐dependent kinase inhibitor targeting transcriptional regulators in acute myeloid leukemia and diffuse large B‐cell lymphoma, as well as antibody–drug conjugates aimed at solid tumors with high unmet medical need.
Founded in 2021 as a spin‐out from an established biotech firm, Whitehawk leverages proprietary discovery platforms and in‐licensing partnerships to accelerate its early‐stage programs through IND‐enabling studies and into human trials. The company’s R&D operations are headquartered in San Diego, California, with additional research collaborations in Boston and European centers of excellence. Through strategic alliances, Whitehawk gains access to specialized technologies and global trial networks, positioning its assets for rapid clinical advancement.
Whitehawk serves a broad geographic footprint, engaging with regulatory authorities and clinical sites across North America, Europe and Asia. The company’s approach emphasizes combination therapy strategies, pairing its novel agents with established checkpoint inhibitors and targeted therapies to maximize efficacy and address resistance mechanisms. Patient enrollment initiatives span leading cancer research centers, enabling Whitehawk to collect robust safety and biomarker data.
Under the leadership of an experienced management team and a board of directors composed of seasoned biopharma executives, Whitehawk Therapeutics is guided by a commitment to scientific rigor and patient‐centric development. Together with its advisory committees—featuring oncology specialists and translational scientists—the company aims to deliver transformational treatments that improve long‐term outcomes for patients battling difficult‐to‐treat cancers.
AI Generated. May Contain Errors.
